133 related articles for article (PubMed ID: 12788077)
1. Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources.
Zień P; Bretner M; Zastapiło K; Szyszka R; Shugar D
Biochem Biophys Res Commun; 2003 Jun; 306(1):129-33. PubMed ID: 12788077
[TBL] [Abstract][Full Text] [Related]
2. Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2.
Zien P; Duncan JS; Skierski J; Bretner M; Litchfield DW; Shugar D
Biochim Biophys Acta; 2005 Dec; 1754(1-2):271-80. PubMed ID: 16203192
[TBL] [Abstract][Full Text] [Related]
3. TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications.
Zień P; Abramczyk O; Domańska K; Bretner M; Szyszka R
Biochem Biophys Res Commun; 2003 Dec; 312(3):623-8. PubMed ID: 14680810
[TBL] [Abstract][Full Text] [Related]
4. Halogenated benzimidazole inhibitors of phosphorylation, in vitro and in vivo, of the surface acidic proteins of the yeast ribosomal 60S subunit by endogenous protein kinases CK-II and PK60S.
Szyszka R; Boguszewska A; Shugar D; Grankowski N
Acta Biochim Pol; 1996; 43(2):389-96. PubMed ID: 8862185
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2').
Sarno S; Reddy H; Meggio F; Ruzzene M; Davies SP; Donella-Deana A; Shugar D; Pinna LA
FEBS Lett; 2001 May; 496(1):44-8. PubMed ID: 11343704
[TBL] [Abstract][Full Text] [Related]
6. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
[TBL] [Abstract][Full Text] [Related]
7. Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources.
Szyszka R; Grankowski N; Felczak K; Shugar D
Biochem Biophys Res Commun; 1995 Mar; 208(1):418-24. PubMed ID: 7887958
[TBL] [Abstract][Full Text] [Related]
8. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses.
Borowski P; Deinert J; Schalinski S; Bretner M; Ginalski K; Kulikowski T; Shugar D
Eur J Biochem; 2003 Apr; 270(8):1645-53. PubMed ID: 12694177
[TBL] [Abstract][Full Text] [Related]
9. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
10. Polyhalogenobenzimidazoles: synthesis and their inhibitory activity against casein kinases.
Andrzejewska M; Pagano MA; Meggio F; Brunati AM; Kazimierczuk Z
Bioorg Med Chem; 2003 Sep; 11(18):3997-4002. PubMed ID: 12927861
[TBL] [Abstract][Full Text] [Related]
11. Catalytic activity of mutants of yeast protein kinase CK2alpha.
Sajnaga E; Kubiński K; Szyszka R
Acta Biochim Pol; 2008; 55(4):767-76. PubMed ID: 19015772
[TBL] [Abstract][Full Text] [Related]
12. Alternative binding modes of an inhibitor to two different kinases.
De Moliner E; Brown NR; Johnson LN
Eur J Biochem; 2003 Aug; 270(15):3174-81. PubMed ID: 12869192
[TBL] [Abstract][Full Text] [Related]
13. New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole.
Bretner M; Najda-Bernatowicz A; Łebska M; Muszyńska G; Kilanowicz A; Sapota A
Mol Cell Biochem; 2008 Sep; 316(1-2):87-9. PubMed ID: 18548199
[TBL] [Abstract][Full Text] [Related]
14. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
15. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
[TBL] [Abstract][Full Text] [Related]
16. Protein kinases phosphorylating acidic ribosomal proteins from yeast cells.
Szyszka R
Folia Microbiol (Praha); 1999; 44(2):142-52. PubMed ID: 10588049
[TBL] [Abstract][Full Text] [Related]
17. Thermodynamic parameters for binding of some halogenated inhibitors of human protein kinase CK2.
Winiewska M; Makowska M; Maj P; Wielechowska M; Bretner M; Poznański J; Shugar D
Biochem Biophys Res Commun; 2015 Jan; 456(1):282-7. PubMed ID: 25450618
[TBL] [Abstract][Full Text] [Related]
18. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
19. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.
Meggio F; Donella Deana A; Ruzzene M; Brunati AM; Cesaro L; Guerra B; Meyer T; Mett H; Fabbro D; Furet P
Eur J Biochem; 1995 Nov; 234(1):317-22. PubMed ID: 8529658
[TBL] [Abstract][Full Text] [Related]
20. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
